Please select the eligibility criteria that correspond to the clinical trial below.
Title: Study of Stress Management and Exercise Intervention During Cancer Chemotherapy
Brief Summary: Chemotherapy adversely affects quality of life in cancer patients. Both stress management training and exercise training have been shown to improve quality of life. These two types of training have not been directly compared for chemotherapy patients.

This study seeks to evaluate the separate and combined effects of stress management training and exercise training on quality of life during chemotherapy treatment. Participants receive either a home-based, self-administered program in 1 of 3 types (stress management, exercise, or stress management + exercise) or usual care (reading materials). It is hypothesized that the combined program (stress management + exercise) will be significantly associated with better quality of life than the usual care group, the exercise only group, and the stress management only group. All participants are assessed at 3 timepoints: before they begin chemotherapy, 6 weeks after their first chemotherapy infusion, and 12 weeks after their first infusion.


Options:
A: Inclusion Criteria:

* Breast cancer early stage I -IIIA
* Completed axillary surgery
* Scheduled to receive adjuvant chemotherapy for 9 - 24 weeks
* Approval of the treating oncologist
* Able to understand and provide written informed consent in English or French (Ottawa)
* 18+ years of age
* No uncontrolled hypertension, cardiac illness, psychiatric condition
* No contraindication to exercise as determined by a fitness test

Exclusion Criteria:

* Pregnant.
* Unwilling to accept randomization.
* Any medical condition that would be a contraindication to exercise. The clinicians will make this decision.
* Unwilling to travel to/participate in the exercise program as defined by the protocol.
* Previous chemotherapy (previous cancer is NOT an exclusion criteria).
* Cancer recurrence.
* Planned/known absence of greater than 2 weeks during the intended study period.
* Previous therapy for known breast cancer.
* Those who have had TRAM (i.e., Transabdominal Rectus Abdominus Muscle Reconstructive Surgery) done.
* Moderate lymphedema (\>20% or \>200mL difference between the affected arm and the unaffected arm).
B: Inclusion Criteria:

1. Legal age (\>18 years old)
2. An interval of at least 6 weeks between prior radical prostatectomy and study enrollment
3. Karnofsky performance status of at least 70% at study entry
4. Estimated life expectancy of ≥6 months
5. Ability to read and understand English
6. Attending urologist approval
7. Signed informed consent
8. Willingness to be randomized; and
9. No contraindications to exercise as recommended by the American Thoracic Society

Exclusion Criteria:

1. Acute myocardial infarction (6 weeks)
2. Unstable angina
3. Uncontrolled arrhythmias causing symptoms or hemodynamic compromise
4. Syncope
5. Acute endocarditis
6. Acute myocarditis or pericarditis
7. Uncontrolled heart failure
8. Acute pulmonary embolus or pulmonary infarction
9. Thrombosis of lower extremities
10. Suspected dissecting aneurysm
11. Uncontrolled asthma
12. Pulmonary edema
13. Room air desaturation at rest ≤85%
14. Respiratory failure
15. Acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise; and
16. Mental impairment leading to inability to cooperate
C: Inclusion Criteria: participants must:

* Be diagnosed with cancer
* Be scheduled to receive cytotoxic chemotherapy for at least 14 weeks
* Be ≥18 years of age or older
* Have an ECOG performance status of 0, 1, or 2
* Be capable of speaking and reading English
* Be able to provide informed consent

Exclusion Criteria:

* ECOG of 3 or greater
* Presence of contraindications to participating in moderate intensity exercise including:

  1. . metastases to weight-bearing sites (spine, pelvis, lower extremities)
  2. . active infections
  3. . cardiomyopathy or congestive heart failure
  4. . severe pulmonary or ventilatory disease (FEV 1.0\<50%)
  5. . large pleural effusions or pericardial effusions
  6. . anemia (Hgb \<8g/dL)
  7. . neutropenia (absolute neutrophil count \< 0.05 x 10(9th)/L)
  8. . severe osteoporosis (\> 2.5 SD below age and gender norms)
  9. . thrombocytopenia (platelets \< 20 x 10(9th)/L)
  10. . hyponatremia (Na+ \< 130 mmol/L)
  11. . hypokalemia (K+ ≤ 3.0 mmol/L)
  12. . hypercalcemia (Ca++ \> 6.5 mmol/L)
  13. . abnormal ECG
  14. . sensorimotor deficits sufficient to impede unassisted walking
* Receipt of intravenous chemotherapy administration in the past 2 months
* Prescription for chronotropic, sympathomimetic, or inotropic/vasoactive medications
* Presence of other contraindications as determined by the attending oncologist and research staff
D: Inclusion Criteria:

* men aged 50 or older
* diagnosed with adenocarcinoma prostate cancer
* will initiate and receive continuous ADT (LHRH or combination of LHRH and anti-androgen for at least 6 months

Exclusion Criteria:

* severe cardiac disease (New York Heart Association class III or greater)
* angina
* severe osteoporosis
* uncontrolled hypertension
* orthostastic blood pressure drop \> 20mm Hg
* moderate to severe aortic stenosis
* acute illness or fever
* uncontrolled atrial or ventricular dysrhythmias
* uncontrolled sinus tachycardia (\> 120 beats per minute)
* uncontrolled congestive heart failure
* third-degree atrio-ventricular heart block
* active pericarditis or myocarditis
* recent embolism, thrombophlebitis
* deep vein thrombosis, resting ST displacement
* uncontrolled diabetes
* uncontrolled pain
* cognitive impairment
* history of falls due to balance impairment or lost of consciousness
* severe neuromusculoskeletal conditions that limit their ability to perform walking exercise

Answer: C